Mucinex Line Extensions Underscore Adams’ Commitment To Building OTCs
This article was originally published in The Tan Sheet
Executive Summary
A major task facing Adams Respiratory Therapeutics' new VP-OTC Marketing & Business Development Robert Casale will be to plan a Fall 2004 launch of extensions to the firm's Mucinex expectorant brand
You may also be interested in...
Adams Pulls Off Trade For Mucinex Complement
Adams Respiratory Therapeutics is expanding its guaifenesin cough/cold portfolio with the addition of Cornerstone BioPharma's Humibid line
Adams execs
Helmut Albrecht, MD, joins Adams Respiratory Therapeutics to serve as senior VP-R&D, the firm announces Oct. 29. Albrecht will oversee all R&D activities, including clinical development, regulatory issues and new product development; the new exec said Adams "is ready to expand its presence in the respiratory category." Most recently, Albrecht was Novartis Consumer Health/OTC business unit's VP-global preclinical & clinical development. New VP-Regulatory Affairs Susan Witham will report to Albrecht. Witham previously held senior positions at J&J Consumer and Novartis. The appointments follow Adams' recently announced strategic decision to focus on OTCs and expand the Mucinex line (1"The Tan Sheet" May 31, 2004, p. 9)...
Adams Labs Taps Former Novartis Exec, CHPA Chair Valentino For CEO Post
Newly appointed Adams Labs CEO Michael Valentino's primary task will be to decide whether to model the firm as an OTC player or maintain its focus on Rx specialty pharmaceuticals